Sorafenib

For research use only. Not for use in humans.

製品コードS7397 別名:BAY 43-9006

Sorafenib化学構造

分子量(MW):464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

サイズ 価格(税別) 在庫  
JPY 26400 あり
JPY 46800 あり
JPY 113200 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(206)

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
ターゲット
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xwc2lEPTB;MD6wNFAxODNyMzFOwG0> NVHaNWV3W0GQR1XS
MONO-MAC-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEC0NVgh|ryP M1fITXNCVkeHUh?=
ALL-PO M2PH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfVTWM2OD1yLkCzNVg1KM7:TR?= NIrGdlFUSU6JRWK=
NKM-1 M1TN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\JfXJKSzVyPUCuNFc1OTZizszN NVq0SXRXW0GQR1XS
CGTH-W-1 NXHydY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjZXYlKSzVyPUCuNlUxOjJizszN MlPTV2FPT0WU
BB65-RCC M4HGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M373OWlEPTB;MD60O|A4OyEQvF2= NEX5TZVUSU6JRWK=
NOS-1 NHzFVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r2ZmlEPTB;MD61OlM3KM7:TR?= NVH3cWc3W0GQR1XS
SH-4 M4Tjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jLdGlEPTB;MD62OVYyOyEQvF2= NVXlOHJPW0GQR1XS
HOP-62 M1XxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPmTWM2OD1yLki1NFg5KM7:TR?= MmjoV2FPT0WU
HCC2998 M13L[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPHTWM2OD1yLki4PFE5KM7:TR?= MYjTRW5ITVJ?
GDM-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;UblhWUUN3ME2wMlkxPjl6IN88US=> NU\QTVFYW0GQR1XS
KM12 NWTCbGM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XyPWlEPTB;MT6wNlA6QCEQvF2= MX3TRW5ITVJ?
LB2518-MEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zOemlEPTB;MT6yNFgxQSEQvF2= NYf2eZJPW0GQR1XS
NCI-H1436 NGDhNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfSTWM2OD1zLkKxOlc5KM7:TR?= NEC1fnBUSU6JRWK=
EM-2 M3jY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXoTWM2OD1zLkO1OVc5KM7:TR?= M2rISnNCVkeHUh?=
LAMA-84 NEKwfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jGR2lEPTB;MT6zO|Y1QCEQvF2= NG\MVpJUSU6JRWK=
KG-1 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofITWM2OD1zLkS3PVM2KM7:TR?= M3LwVHNCVkeHUh?=
A388 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwNUmxOlUh|ryP NGPVU4ZUSU6JRWK=
no-10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L3TmlEPTB;MT62NVczPiEQvF2= NYDr[YdwW0GQR1XS
SF126 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j4[2lEPTB;MT62N|gyOiEQvF2= NGjWSWpUSU6JRWK=
MEG-01 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzjTWM2OD1zLkiwPVgh|ryP NXzIN4RWW0GQR1XS
A3-KAW NYrDVFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:3eI46UUN3ME2xMlg5PDJizszN NYXMSnJ[W0GQR1XS
D-247MG M4DNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\4TWM2OD1{LkG0OFgh|ryP NXHSfFc6W0GQR1XS
OVCAR-4 NHvxOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnvV5NKSzVyPUKuNlE{QTNizszN MUTTRW5ITVJ?
NCI-SNU-1 NVHZdIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnTTWM2OD1{LkOxOlIh|ryP Ml36V2FPT0WU
NCI-H2171 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnHTWM2OD1{LkO5O|Y1KM7:TR?= NGPueJZUSU6JRWK=
SIG-M5 NYnycnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DWZ2lEPTB;Mj60NlI1OiEQvF2= MmPoV2FPT0WU
BE-13 M2Lj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwNkm2NFkh|ryP NEPiO4VUSU6JRWK=
K052 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorBTWM2OD1{Lke0OlE3KM7:TR?= NIPwRWFUSU6JRWK=
L-540 M3HWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i3eWlEPTB;Mj63OVc5QSEQvF2= MoXJV2FPT0WU
KMOE-2 NXzud5Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rqbGlEPTB;Mj64NVM2KM7:TR?= MV\TRW5ITVJ?
MFH-ino NIrFU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3BTWM2OD1{LkmyNVg2KM7:TR?= NWLTOFZEW0GQR1XS
HL-60 NEnaeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwME[yPVkh|ryP M3nDTXNCVkeHUh?=
HCC2218 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNwMUKwNFMh|ryP Mmr1V2FPT0WU
TE-5 M1L0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n6NGlEPTB;Mz6xN|E3OiEQvF2= MnTjV2FPT0WU
MZ1-PC NF3Fd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q4U2lEPTB;Mz60O|UxQSEQvF2= NH3GW3VUSU6JRWK=
MRK-nu-1 MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7TfYJKSzVyPUOuOlE1PjhizszN M3vGV3NCVkeHUh?=
MZ7-mel NUT5R4NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\3TI9WUUN3ME2zMlY3ODl7IN88US=> NWDHco42W0GQR1XS
BC-1 M3rSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP2RYpGUUN3ME2zMlc1ODJizszN NGnFNWlUSU6JRWK=
ST486 M{jTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoToTWM2OD1|LkizOlc{KM7:TR?= M4i3VHNCVkeHUh?=
KS-1 M3rDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3viZWlEPTB;Mz64PFE6QCEQvF2= M2WySXNCVkeHUh?=
SK-NEP-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPmTFZKSzVyPUSuNVY5OTVizszN MkSyV2FPT0WU
BC-3 NInjeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXaTmZKSzVyPUSuNlM{QTFizszN NGLNRphUSU6JRWK=
NCI-H1581 M1nFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KyS2lEPTB;ND6yPFc6QCEQvF2= M1T0NXNCVkeHUh?=
MHH-PREB-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTRwNEC0PFQh|ryP MWjTRW5ITVJ?
NOMO-1 M{XRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGezdW9KSzVyPUSuOFg6ODVizszN NFT5dYpUSU6JRWK=
QIMR-WIL NUTmc4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTVwMEeyPVQh|ryP M37pcXNCVkeHUh?=
SF539 NHnXNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f5cmlEPTB;NT6xN|IzPyEQvF2= NE[zc5FUSU6JRWK=
TE-12 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTVwMkS5Nlkh|ryP NV:4SYJ7W0GQR1XS
NCI-H510A MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXQVpVKSzVyPUWuOFE3QDVizszN MnX4V2FPT0WU
JAR M2rRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16xUWlEPTB;NT61NFgzPCEQvF2= NFjoZmtUSU6JRWK=
no-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfCZnpKSzVyPUWuO|M2PjhizszN NYPaPFUyW0GQR1XS
BV-173 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTVwOUW2PFIh|ryP MV\TRW5ITVJ?
SR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTydJFEUUN3ME22MlAxPjd6IN88US=> NGq0RWlUSU6JRWK=
MOLT-16 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[3dGlEPTB;Nj6yOVI3PiEQvF2= MYXTRW5ITVJ?
MZ2-MEL M3njN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHsTWM2OD14LkOxPFM6KM7:TR?= M2myeXNCVkeHUh?=
SW954 NU\DO3ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDmNmJKSzVyPU[uOFU5PjZizszN NUjSdXZZW0GQR1XS
ML-2 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mzSGlEPTB;Nj61Nlg1QSEQvF2= MkHFV2FPT0WU
OCI-AML2 M4\rN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O2W2lEPTB;Nj62NVA3OiEQvF2= MkHFV2FPT0WU
SIMA NYXBPG55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrrOHRKSzVyPUeuNFAyODFizszN M3TRVHNCVkeHUh?=
DOHH-2 NHu2XY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrRTWM2OD15LkC1Olc3KM7:TR?= NIC2RZRUSU6JRWK=
697 NILHd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTWTWM2OD15LkC1PVg6KM7:TR?= MYTTRW5ITVJ?
NB1 NUjRPHY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjIfJA{UUN3ME23MlQxPDB5IN88US=> MUfTRW5ITVJ?
D-392MG NX;Jbop2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTdwNkK2OlMh|ryP NGixS3dUSU6JRWK=
ES8 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n2S2lEPTB;Nz63OlUxOyEQvF2= Mo[zV2FPT0WU
RPMI-8226 NF7PUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDVTWM2OD15Lki0OVEyKM7:TR?= MX\TRW5ITVJ?
IST-MEL1 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LuSWlEPTB;OD60NFAxOiEQvF2= MWrTRW5ITVJ?
NB14 M1;yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PZcGlEPTB;OD62N|E{OyEQvF2= MnnBV2FPT0WU
HD-MY-Z NITJXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofCTWM2OD16Lk[zO|Q3KM7:TR?= M{LyW3NCVkeHUh?=
TE-10 NETXOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTRVmZKSzVyPUiuO|Y{PTNizszN MYLTRW5ITVJ?
LC-1F NFfZdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDYVpBPUUN3ME25MlExQDN2IN88US=> M{n6ZnNCVkeHUh?=
OS-RC-2 M1ywN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rHZ2lEPTB;OT6xNVI1OyEQvF2= NH\YN41USU6JRWK=
NCI-SNU-16 NUiyVGVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n4b2lEPTB;OT6yNVAzPiEQvF2= M2m2UnNCVkeHUh?=
SHP-77 NV65OWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTGV5RKSzVyPUmuO|E3PjJizszN M{WydHNCVkeHUh?=
A4-Fuk NHfSfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TGbWlEPTB;OT63OVYyKM7:TR?= M4PZbnNCVkeHUh?=
NB6 NFHWU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHvVZlKSzVyPUmuO|YxOjlizszN NUX0V41mW0GQR1XS
JiyoyeP-2003 NFjh[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H2PGlEPTB;MUCuOFc1PSEQvF2= NEHje|BUSU6JRWK=
DMS-114 MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH0TWM2OD1zMD61OFQyKM7:TR?= Mle0V2FPT0WU
NB7 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PtVmlEPTB;MUCuO|UzPiEQvF2= M3faXHNCVkeHUh?=
NCI-H747 NV72T4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPlUnpKSzVyPUGxMlEzOTZizszN NHHaeXJUSU6JRWK=
HH MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m3bWlEPTB;MUGuN|g4PiEQvF2= NIDIWYVUSU6JRWK=
EW-18 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi4TWM2OD1zMT65NFQ1KM7:TR?= NITQT3hUSU6JRWK=
CHP-126 MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLYWGxtUUN3ME2xNU46PzN6IN88US=> MlznV2FPT0WU
NTERA-S-cl-D1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7rUIlKSzVyPUGyMlAzPzhizszN NYq2WHRsW0GQR1XS
DEL MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX0fVFxUUN3ME2xNk4xQTh3IN88US=> MlK5V2FPT0WU
LU-139 NIjCfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF{LkW0NVMh|ryP MUDTRW5ITVJ?
P30-OHK M3z0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLtTWM2OD1zMj61OFc6KM7:TR?= M4DmTXNCVkeHUh?=
NCI-H1522 M4[zS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rWTWlEPTB;MUKuO|Q3KM7:TR?= M1\HZnNCVkeHUh?=
NCI-H1299 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULR[4c1UUN3ME2xN{4zQTFzIN88US=> M17UZ3NCVkeHUh?=
UACC-257 NUD1c5Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX2cppXUUN3ME2xN{42OTJ4IN88US=> MXHTRW5ITVJ?
Calu-6 M2fQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLWWpdZUUN3ME2xN{43ODR4IN88US=> NFzV[XhUSU6JRWK=
NCI-H1882 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF|Lki1OVUh|ryP Ml\PV2FPT0WU
BB30-HNC NEO5O2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF2LkC2NFkh|ryP NGrDUWRUSU6JRWK=
ES1 NHnJTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF2LkG1OVEh|ryP NYDoXZd2W0GQR1XS
NCI-H1694 NUPNT5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vUfWlEPTB;MUSuOFgyOSEQvF2= NFHoUlZUSU6JRWK=
IST-SL1 NYXE[oVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrwfFRKSzVyPUG0Mlk3OTZizszN Ml:1V2FPT0WU
ECC4 NIPxXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnexTWM2OD1zNT6wOVU5KM7:TR?= Ml21V2FPT0WU
MDA-MB-134-VI MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrvTWM2OD1zNT60NVMyKM7:TR?= M{TCN3NCVkeHUh?=
SCH NHvseYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPkc|VKSzVyPUG1MlQ4OjhizszN NHvkeYNUSU6JRWK=
SK-N-FI MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWft[olXUUN3ME2xOU43PTN2IN88US=> MknMV2FPT0WU
HDLM-2 NXjuUIhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLsTWM2OD1zNj6wO|E1KM7:TR?= NIfnZpNUSU6JRWK=
Ramos-2G6-4C10 NY[4ZolzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv5bIZ2UUN3ME2xOk4yOjl5IN88US=> NYf2O|Y4W0GQR1XS
EW-24 NWTyPJpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\FTWM2OD1zNj6xOlYyKM7:TR?= NWj3W5RmW0GQR1XS
NCI-H2141 NGTpcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF4LkG4PUDPxE1? NXTWfocxW0GQR1XS
LC4-1 NFrhbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrwd5BKSzVyPUG2MlYyOTlizszN MVvTRW5ITVJ?
HT-144 NFzBUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTKWIVOUUN3ME2xO{4xODZizszN NVvZUFhmW0GQR1XS
SK-MEL-1 NYe0RlJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3niSGlEPTB;MUeuNFA4OiEQvF2= M1TWd3NCVkeHUh?=
SCC-15 NWDwWYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewbYI4UUN3ME2xO{4yPjN6IN88US=> M3jtfnNCVkeHUh?=
C8166 NEXCZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF5Lk[4N|Mh|ryP NXnn[mRGW0GQR1XS
GOTO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD1zNz64N|Q1KM7:TR?= NXzlbHFxW0GQR1XS
COR-L279 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7PWYJwUUN3ME2xPE4yOzZ{IN88US=> MYLTRW5ITVJ?
K-562 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS0SolyUUN3ME2xPE44OTR|IN88US=> M1TsZnNCVkeHUh?=
ES3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF6LkiwOFEh|ryP MkDSV2FPT0WU
LU-165 NGXESYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITHPFZKSzVyPUG5MlcxODhizszN NY[1XlhNW0GQR1XS
KM-H2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJyLkOxPFQh|ryP M3T6bXNCVkeHUh?=
RL NHzuWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH4Wm5wUUN3ME2yNE46Pjl{IN88US=> MX7TRW5ITVJ?
EW-3 NYTvZoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfUT4ZJUUN3ME2yNU4yQDh7IN88US=> MlrGV2FPT0WU
A101D NH\NXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorOTWM2OD1{MT6zO|UzKM7:TR?= NXj1SI9pW0GQR1XS
HUTU-80 NHTUfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPITWM2OD1{MT6zPVQ3KM7:TR?= NH3yb4FUSU6JRWK=
NCI-H23 NXzLfVZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDSTWM2OD1{MT6zPVkzKM7:TR?= MXjTRW5ITVJ?
PF-382 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q3WWlEPTB;MkGuOFQxOyEQvF2= M4Xzd3NCVkeHUh?=
LB373-MEL-D NUP4VohiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16wOmlEPTB;MkGuOVYyPSEQvF2= M1X0R3NCVkeHUh?=
TE-8 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTRem5zUUN3ME2yNU43Ozl2IN88US=> MVLTRW5ITVJ?
TE-9 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:3OmlEPTB;MkGuPFUyOyEQvF2= MnzvV2FPT0WU
Daudi MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj6fpJKSzVyPUKxMlk{ODRizszN NYLYc|l[W0GQR1XS
D-542MG NIGyWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\FTWM2OD1{Mj6wNlU3KM7:TR?= NUjRS481W0GQR1XS
U-698-M NFXvfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\tZ3VKSzVyPUKyMlQ3ODNizszN MmraV2FPT0WU
ES6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnWeIhMUUN3ME2yNk44OzZ4IN88US=> NVXTPZFCW0GQR1XS
DU-4475 NUDPb3VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXWWVFIUUN3ME2yN{45QDl5IN88US=> NVnPU4NHW0GQR1XS
ECC12 NWXiUnVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ2LkK4NFMh|ryP M1nTOHNCVkeHUh?=
C2BBe1 NF:yWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ2LkOyN|kh|ryP NHy5[VBUSU6JRWK=
IST-SL2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;3SG5KSzVyPUK0MlQ{PjJizszN NEnNbWVUSU6JRWK=
DJM-1 NU\vUnpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn0bJRKSzVyPUK0MlUzOjFizszN MlzBV2FPT0WU
DMS-153 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ2Lki2NVQh|ryP MU\TRW5ITVJ?
NB13 NV;FPJJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;vS2lEPTB;MkWuNFI3PSEQvF2= MVzTRW5ITVJ?
SK-N-DZ NWHEVYFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ4LkO0NVQh|ryP NWf1RXRKW0GQR1XS
COR-L88 M4S0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ4LkW3PVYh|ryP M3nUWHNCVkeHUh?=
LU-65 M1KyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nVRmlEPTB;Mk[uPFU{PSEQvF2= Mn;lV2FPT0WU
TGBC1TKB M{HMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvmTWM2OD1{Nj65PFI5KM7:TR?= NGm0b2lUSU6JRWK=
THP-1 NFnzVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnFTWM2OD1{Nz6yNVQyKM7:TR?= NYPkN4VRW0GQR1XS
ONS-76 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ5LkOzNkDPxE1? NH\sNpVUSU6JRWK=
LC-2-ad M4jUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Q[YliUUN3ME2yO{43OjNzIN88US=> NWGxO2w{W0GQR1XS
EW-13 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ7LkG3OFYh|ryP M3[zb3NCVkeHUh?=
MS-1 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LFc2lEPTB;M{CuO|I4QCEQvF2= MV3TRW5ITVJ?
NCI-H2227 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHwTWM2OD1|MD65PFA3KM7:TR?= NWrvPVlSW0GQR1XS
LXF-289 M{nCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNzLkS0PVIh|ryP NIXxb2JUSU6JRWK=
MC116 NWfUcXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG5TWM2OD1|Mj6wPFI3KM7:TR?= MUfTRW5ITVJ?
EVSA-T MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTN{LkK1PFUh|ryP M2nnTHNCVkeHUh?=
CTB-1 NG\T[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN|LkGxNFEh|ryP M1PyOnNCVkeHUh?=
COLO-320-HSR NXLqOY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jtRmlEPTB;M{OuNVYxOyEQvF2= MVjTRW5ITVJ?
NCI-H2196 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rRcmlEPTB;M{OuNlU2PyEQvF2= MnW2V2FPT0WU
LB2241-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n2bWlEPTB;M{OuN|E{PSEQvF2= M4PNWXNCVkeHUh?=
LS-513 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3WxWWlEPTB;M{OuPFY{QCEQvF2= Ml;0V2FPT0WU
LP-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmwTWM2OD1|Mz65PVU3KM7:TR?= Ml7HV2FPT0WU
A253 NFjTd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEezcZpKSzVyPUO0MlIzQTZizszN MVXTRW5ITVJ?
SK-MM-2 NGPadGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN2Lkm0OVEh|ryP MnHZV2FPT0WU
NCI-H1963 MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTN3LkOwO|Ih|ryP MXHTRW5ITVJ?
MMAC-SF MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1R3NKSzVyPUO1Mlg4QDVizszN NVrNdINjW0GQR1XS
LB831-BLC NF;WeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP2TZpKSzVyPUO2MlA3PTRizszN MX3TRW5ITVJ?
WSU-NHL M{fuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTN4LkG2OEDPxE1? NFnvOlFUSU6JRWK=
CESS NVPiXW5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXUdm1KSzVyPUO2MlI5PDhizszN MmLMV2FPT0WU
NEC8 NYnK[WNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXmVHhKSzVyPUO2MlU5OzVizszN M{\NW3NCVkeHUh?=
KNS-42 NFfZd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L3UWlEPTB;M{euNVI{PyEQvF2= M1niTXNCVkeHUh?=
MHH-CALL-2 NELpUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\4UHBLUUN3ME2zO{4yQDJzIN88US=> NFzIfG1USU6JRWK=
K5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PWWmlEPTB;M{iuOFMh|ryP NXO4XpY4W0GQR1XS
CP66-MEL NFXUXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\jVHVUUUN3ME2zPU4xPzN|IN88US=> NHjWSGlUSU6JRWK=
OPM-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKyTWM2OD1|OT64OFMzKM7:TR?= M{HPbHNCVkeHUh?=
IST-MES1 NH;WZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLuWXRKSzVyPUSwMlMxQTZizszN MlfuV2FPT0WU
EC-GI-10 NGHGZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTRzLkW4NFUh|ryP NV;0VVVCW0GQR1XS
CTV-1 M{HnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3JVnFKSzVyPUSyMlg1ODZizszN NEm0U29USU6JRWK=
DG-75 M3rzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTR|Lke1PVUh|ryP NYHpVZpUW0GQR1XS
KNS-81-FD MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTR3LkSwOVgh|ryP M2K5NXNCVkeHUh?=
NCI-H82 NEfK[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLPTWM2OD12NT61O|U5KM7:TR?= MlvTV2FPT0WU
RPMI-8866 NFO1RW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:wZpRnUUN3ME20Ok4yQDd|IN88US=> NYLtdo8{W0GQR1XS
ACN MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjjTWM2OD12Nj60N|Qh|ryP NGTvWWtUSU6JRWK=
NCI-H1395 Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;kRYhKSzVyPUS2MlQ4PTZizszN NWLteI42W0GQR1XS
NCI-H209 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVztVnozUUN3ME20O{4yPDB3IN88US=> MonUV2FPT0WU
TGW NVnpSVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTR7LkC3PVEh|ryP NYP1NYVPW0GQR1XS
NCI-H748 NWfQUFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nrUmlEPTB;NEmuOFc2OyEQvF2= NFTMfoZUSU6JRWK=
EKVX MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR7Lk[2Nlgh|ryP M1:5W3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
体内試験 Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験:

[1]

- 合併
  • 細胞株: MDA-MB-231, and HAoSMC
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (参考用のみ)
動物試験:

[1]

- 合併
  • 動物モデル: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • 製剤: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • 投薬量: ~60 mg/kg
  • 投与方法: Orally once daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 63 mg/mL (135.53 mM) warming
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+45% PEG 400+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 464.82
化学式

C21H16ClF3N4O3

CAS No. 284461-73-0
保管
in solvent
別名 BAY 43-9006
Smiles CNC(=O)C1=CC(=CC=N1)OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000737 Not yet recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. August 15 2019 Phase 2
NCT03958669 Not yet recruiting -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research July 1 2019 --
NCT03764293 Not yet recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. January 2019 Phase 3
NCT03582618 Recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

Rafシグナル伝達経路

相関Raf製品

Tags: Sorafenibを買う | Sorafenib ic50 | Sorafenib供給者 | Sorafenibを購入する | Sorafenib費用 | Sorafenib生産者 | オーダーSorafenib | Sorafenib化学構造 | Sorafenib分子量 | Sorafenib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID